AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

Conditions

Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

Trial Timeline

Jul 1, 2013 → Dec 1, 2013

About AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension

AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension is a phase 1 stage product being developed by AstraZeneca for Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax. The current trial status is completed. This product is registered under clinical trial identifier NCT01889160. Target conditions include Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01889160Phase 1Completed